CoChat
Sign Up
Cited by 660Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsEndometriosis Research and Treatment

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation1

Moghetti, Paolo, Castello, Roberto, Negri, Carlo, Tosi, Flavia, Perrone, Fabrizia, Caputo, Marco, Zanolin, Elisabetta, Muggeo, Michele·2000·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.85.1.6293
Open this paper in CoChat — free account

Abstract

In the last few years some studies assessed the effects of attenuation of hyperinsulinemia and insulin resistance, obtained by insulin sensitizing agents, in women with polycystic ovary syndrome (PCOS), suggesting potential scope for these drugs in treating the whole spectrum of reproductive, endocrine, and metabolic abnormalities found in such subjects. However, the results of these studies, mostly uncontrolled and short-term, are still inconclusive, and there is no long-term follow-up. In the present study, 23 PCOS subjects [mean (+/- SE) body mass index 30.0+/-1.1 kg/m2] were randomly assigned to double-blind treatment with metformin (500 mg tid) or placebo for 6 months, while maintaining their usual eating habits. Before and after treatment, menstrual history, endocrine and metabolic profiles, serum 17-hydroxyprogesterone response to GnRH-agonist testing, and insulin sensitivity measured by the glucose clamp technique were assessed. Eighteen of these women, as well as 14 additional PCOS patients, were subsequently given metformin in an open trial for 11.0+/-1.3 months (range 4-26), to assess long-term effects of treatment and baseline predictors of metformin efficacy on reproductive abnormalities. After metformin treatment, mean frequency of menstruation improved (P = 0.002), due to striking amelioration of menstrual abnormalities in about 50% of subjects. Women given metformin showed reduced plasma insulin (at fasting: P = 0.057; during the clamp studies: P<0.01) and inc…

Overview

Integrity signals

Registry

Crossref · 10.1210/jcem.85.1.6293

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 6 references

Cited by

Sorted by citations

Metadata

Authors
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M.
Affiliations
University of Verona (IT)
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2000-01
Volume
85
Issue
1
Pages
139-146
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.85.1.6293
OpenAlex
W2165523894
Cited by
660
References
6
Citations by year
2026: 3 · 2025: 4 · 2024: 1 · 2023: 12 · 2022: 11 · 2021: 20 · 2020: 9 · 2019: 15 · 2018: 14 · 2017: 15 · 2016: 19 · 2015: 16 · 2014: 16 · 2013: 35 · 2012: 26
FWCI
58.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
metformin, polycystic ovary syndrome, insulin resistance, insulin sensitivity, hyperinsulinemia, menstrual disorders, ovarian hyperandrogenism, free testosterone, 17-hydroxyprogesterone, GnRH agonist stimulation, glucose clamp, long-term treatment outcomes, predictors of treatment response, body mass index, insulin sensitizers, long-term follow-up
MeSH terms
Adolescent, Adult, Blood Glucose, Buserelin, Cholesterol, Double-Blind Method, Endocrine Glands, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Insulin Resistance, Gonadotropin-Releasing Hormone, Menstruation Disturbances, Metformin, Polycystic Ovary Syndrome, Triglycerides, Glucose Clamp Technique, 17-alpha-Hydroxyprogesterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review